Literature DB >> 30564919

Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients.

Maura Statzu1, Letizia Santinelli1, Agnese Viscido1, Claudia Pinacchio2, Giancarlo Ceccarelli2, Claudia Rotondo1, Giuseppe Corano Scheri2, Ivano Mezzaroma3, Ombretta Turriziani1, Guido Antonelli1, Gabriella d'Ettorre2, Carolina Scagnolari4.   

Abstract

PURPOSE: To investigate the contribution of SAMHD1 to HIV-1 infection in vivo and its relationship with IFN response, the expression of SAMHD1 and IFN-related pathways was evaluated in HIV-1-infected patients.
METHODS: Peripheral blood mononuclear cells (PBMC) from 388 HIV-1-infected patients, both therapy naïve (n = 92) and long-term HAART treated (n = 296), and from 100 gender and age-matched healthy individuals were examined. CD4+ T cells, CD14+ monocytes and gut biopsies were also analyzed in HIV-1-infected subjects on suppressive antiretroviral therapy. Gene expression levels of SAMDH1, ISGs (MxA, MxB, HERC5, IRF7) and IRF3 were evaluated by real-time RT-PCR assays.
RESULTS: SAMHD1 levels in HIV-1-positive patients were significantly increased compared to those in healthy donors. SAMHD1 expression was enhanced in treated patients compared to naïve patients (p < 0.0001) and healthy donors (p = 0.0038). Virologically suppressed treated patients exhibited higher SAMHD1 levels than healthy donors (p = 0.0008), viraemic patients (p = 0.0001) and naïve patients (p < 0.0001). SAMHD1 levels were also increased in CD4+ T cells compared to those in CD14+ monocytes and in PBMC compared to those of GALT. Moreover, SAMHD1 was expressed more strongly than ISGs in HIV-1-infected patients and positive correlations were found between SAMHD1, ISGs and IRF3 levels.
CONCLUSIONS: SAMHD1 is more strongly expressed than the classical IFN-related genes, increased during antiretroviral therapy and correlated with ISGs and IRF3 in HIV-1-infected patients.

Entities:  

Keywords:  HIV-1; IFN; IRF3; ISG; SAMHD1

Mesh:

Substances:

Year:  2018        PMID: 30564919     DOI: 10.1007/s00430-018-0574-x

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   4.148


  69 in total

1.  SAMHD1 expression in blood cells of HIV-1 elite suppressors and viraemic progressors.

Authors:  Erin L Buchanan; Melissa A McAlexander; Kenneth W Witwer
Journal:  J Antimicrob Chemother       Date:  2014-10-23       Impact factor: 5.790

2.  A new activity for SAMHD1 in HIV restriction.

Authors:  Zhiyuan Yang; Warner C Greene
Journal:  Nat Med       Date:  2014-08       Impact factor: 53.440

3.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates.

Authors:  Hichem Lahouassa; Waaqo Daddacha; Henning Hofmann; Diana Ayinde; Eric C Logue; Loïc Dragin; Nicolin Bloch; Claire Maudet; Matthieu Bertrand; Thomas Gramberg; Gianfranco Pancino; Stéphane Priet; Bruno Canard; Nadine Laguette; Monsef Benkirane; Catherine Transy; Nathaniel R Landau; Baek Kim; Florence Margottin-Goguet
Journal:  Nat Immunol       Date:  2012-02-12       Impact factor: 25.606

4.  Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis.

Authors:  Alexandre Sze; S Mehdi Belgnaoui; David Olagnier; Rongtuan Lin; John Hiscott; Julien van Grevenynghe
Journal:  Cell Host Microbe       Date:  2013-10-16       Impact factor: 21.023

5.  Low SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1.

Authors:  Nicolas Ruffin; Vedran Brezar; Diana Ayinde; Cécile Lefebvre; Julian Schulze Zur Wiesch; Jan van Lunzen; Maximilian Bockhorn; Olivier Schwartz; Hakim Hocini; Jean-Daniel Lelievre; Jacques Banchereau; Yves Levy; Nabila Seddiki
Journal:  AIDS       Date:  2015-03-13       Impact factor: 4.177

6.  T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naïve chronic HIV-1 patients.

Authors:  Sebastian Bolduan; Herwig Koppensteiner; Ramona Businger; Stephanie Rebensburg; Christine Kunze; Ruth Brack-Werner; Rika Draenert; Michael Schindler
Journal:  J Int AIDS Soc       Date:  2017-09-19       Impact factor: 5.396

7.  SAMHD1's protein expression profile in humans.

Authors:  Sarah Schmidt; Kristina Schenkova; Tarek Adam; Elina Erikson; Judith Lehmann-Koch; Serkan Sertel; Bruno Verhasselt; Oliver T Fackler; Felix Lasitschka; Oliver T Keppler
Journal:  J Leukoc Biol       Date:  2015-02-02       Impact factor: 4.962

8.  Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply.

Authors:  Loic Dragin; Laura Anh Nguyen; Hichem Lahouassa; Adèle Sourisce; Baek Kim; Bertha Cecilia Ramirez; Florence Margottin-Goguet
Journal:  Retrovirology       Date:  2013-03-11       Impact factor: 4.602

9.  The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals.

Authors:  Hangxing Yu; Shariq M Usmani; Alexandra Borch; Julia Krämer; Christina M Stürzel; Mohammad Khalid; Xuehua Li; Daniela Krnavek; Marchina E van der Ende; Albert D Osterhaus; Rob A Gruters; Frank Kirchhoff
Journal:  Retrovirology       Date:  2013-03-05       Impact factor: 4.602

10.  A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features.

Authors:  Y M El-Sherbiny; A Psarras; M Y Md Yusof; E M A Hensor; R Tooze; G Doody; A A A Mohamed; D McGonagle; M Wittmann; P Emery; E M Vital
Journal:  Sci Rep       Date:  2018-04-11       Impact factor: 4.996

View more
  1 in total

1.  Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.

Authors:  Gabriella d'Ettorre; Gregorio Recchia; Marco Ridolfi; Guido Siccardi; Claudia Pinacchio; Giuseppe Pietro Innocenti; Letizia Santinelli; Federica Frasca; Camilla Bitossi; Giancarlo Ceccarelli; Cristian Borrazzo; Guido Antonelli; Carolina Scagnolari; Claudio Maria Mastroianni
Journal:  Medicine (Baltimore)       Date:  2020-09-04       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.